Clearmind Medicine (Clearmind Medicine) Cash-to-Debt : 98.66 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clearmind Medicine's cash to debt ratio for the quarter that ended in Jan. 2024 was 98.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Clearmind Medicine could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Clearmind Medicine's Cash-to-Debt or its related term are showing as below:

CMND' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.46 Med: No Debt Max: No Debt
Current: 98.66

During the past 7 years, Clearmind Medicine's highest Cash to Debt Ratio was No Debt. The lowest was 8.46. And the median was No Debt.

CMND's Cash-to-Debt is ranked better than
78.13% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs CMND: 98.66

Clearmind Medicine Cash-to-Debt Historical Data

The historical data trend for Clearmind Medicine's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Clearmind Medicine Cash-to-Debt Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

8.46

No Debt

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															174.75	985.00	No Debt	No Debt	98.66

Competitive Comparison of Clearmind Medicine's Cash-to-Debt

For the Biotechnology subindustry, Clearmind Medicine's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Cash-to-Debt falls into.

Clearmind Medicine Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Clearmind Medicine's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Clearmind Medicine had no debt ⁽¹⁾.

Clearmind Medicine's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.373	/	(0.064	+	0.031)
	=	98.66

Clearmind Medicine (NAS:CMND) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Clearmind Medicine Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.